Literature DB >> 10997987

A case of purpura fulminans is caused by homozygous delta8857 mutation (protein C-nagoya) and successfully treated with activated protein C concentrate.

T Nakayama1, T Matsushita, H Hidano, C Suzuki, M Hamaguchi, T Kojima, H Saito.   

Abstract

We report a Japanese patient who developed purpura fulminans and disseminated intravascular coagulation (DIC) shortly after birth. The patient was diagnosed to be homozygous for protein C deficiency and was treated with an activated protein C (APC) concentrate. Intravenous infusions of APC markedly improved the necrotic skin lesions and the anticoagulation by APC enabled successful DIC control. The identified mutation (Delta8857) results in impaired intracellular transport and protein maturation and would be the cause of the complete protein C deficiency. This is the seventh case of the mutation that has been exclusively reported in Japan, but is the first report of a homozygous case. Our findings propose new therapeutic and diagnostic tools for the management of this fatal thrombotic disease.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10997987     DOI: 10.1046/j.1365-2141.2000.02230.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  4 in total

1.  Myeloid/natural killer cell precursor acute leukemia accompanied by homozygous protein C deficiency.

Authors:  Takashi Shimamoto; Akihiro Nakajima; Tomoko Katagiri; Yoshikazu Ito; Kazuma Ohyashiki
Journal:  Int J Hematol       Date:  2003-08       Impact factor: 2.490

2.  Definite diagnosis in Japanese patients with protein C deficiency by identification of causative PROC mutations.

Authors:  Akira Takagi; Ryoko Tanaka; Daisuke Nakashima; Yuta Fujimori; Takayuki Yamada; Kaoru Okumura; Takashi Murate; Midori Yamada; Yasuo Horikoshi; Koji Yamamoto; Akira Katsumi; Tadashi Matsushita; Tomoki Naoe; Tetsuhito Kojima
Journal:  Int J Hematol       Date:  2009-04-17       Impact factor: 2.490

3.  Use of human protein C concentrates in the treatment of patients with severe congenital protein C deficiency.

Authors:  Sabine Kroiss; Manuela Albisetti
Journal:  Biologics       Date:  2010-03-24

4.  Severe congenital protein C deficiency: the use of protein C concentrates (human) as replacement therapy for life-threatening blood-clotting complications.

Authors:  Paul N Knoebl
Journal:  Biologics       Date:  2008-06
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.